Novo Nordisk Canada launches an Ozempic savings card to match generic pricing

Novo Nordisk Canada introduced a savings card on August 17, 2026, aimed at bringing the brand-name price of Ozempic down to roughly what generic semaglutide costs for uninsured Canadians ^[1]. The card is distributed through Rexall pharmacies and does not apply in Quebec ^[1][2].

The move is a direct response to competition. Dr. Reddy's generic semaglutide reached Canadian pharmacies on May 15, 2026, becoming available months after Health Canada approved it ^[2]. Canada's patent situation differs sharply from the United States: Novo Nordisk stopped paying a roughly $C250 annual patent maintenance fee in 2018, and that lapse, combined with a separate regulatory approval requirement that expired in January 2026, opened the door for generic manufacturers to file for approval ^[2]. Novo Nordisk has not fully explained why the fee went unpaid, telling The BMJ only that "all intellectual property decisions are carefully considered at the global level" ^[2]. Mina Tadrous, a University of Toronto pharmacist and drug policy researcher, told The BMJ the lapse may have been "a strategy on their part," noting the decision predated the full commercial boom in semaglutide sales ^[2].

Canadian generic pricing follows a set formula tied to the number of competitors on the market: prices fall to 75% of the brand list price with one generic, 50% with two, and 35% once three or more generics are available ^[2]. Tadrous estimated that once three generics reach the market, monthly out-of-pocket costs in Canada could fall to around $C100 ^[2]. As of the reporting, brand-name Ozempic prices tracked across Canadian pharmacies ranged from $86.40 to $663 CAD, and Wegovy ranged from $270 to $550 CAD ^[2]. Despite the new competition, Tadrous said he expects Novo Nordisk to hold onto more market share after generic entry than is typical for a brand facing generic competition ^[1][2].

The pricing pressure is showing up in Novo Nordisk's global numbers. The company forecast that 2026 sales would fall between 5% and 13%, ending years of double-digit growth, and its share price dropped 17% on the day that guidance was announced ^[2]. CEO Mike Doustdar described 2026 as a year of "unprecedented pricing pressure" ^[2]. Semaglutide products earned Novo Nordisk roughly $29 billion in 2024, with $17.5 billion of that coming from Ozempic alone ^[2], underscoring how much is riding on the company's response to generic competition.

Why it matters for patients

This development is specific to Canada and does not change anything for U.S. patients right now. Novo Nordisk has stated that the Canadian situation is "a localized situation based on our specific patent timelines and regulatory environment" and does not reflect the U.S., where semaglutide exclusivity remains intact until 2032 ^[2]. Patent protection for semaglutide also runs until 2033 in Europe and Japan ^[2]. For Americans following GLP-1 pricing news, the Canadian episode is a preview of what could eventually unfold once U.S. patents lapse, but it also shows that brand manufacturers can respond to generic entry with targeted discount programs rather than simply ceding the market. It's a reminder that list prices, insurance status, and patent timelines vary enormously by country, and price comparisons across borders don't translate directly.

What happens next

Seven additional generic semaglutide applications remained under Health Canada review as of the reporting, and Apotex, a second approved generic manufacturer, had not yet announced a Canadian release date at the time this savings card launched ^[2]. Eli Lilly's tirzepatide products, sold as Mounjaro and Zepbound, are projected to overtake semaglutide as the leading GLP-1 medications within the next few years, according to reporting cited by The BMJ ^[2].